Drug intelligence / Profile preview

CS-2036

Development stage: Phase 1
Lead developer: CanSino Biologics
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**CS-2036** is a recombinant trivalent poliomyelitis vaccine developed by CanSino Biologics, utilizing a non-infectious virus-like particle (VLP) approach based on Sf-RVN cells to mimic poliovirus structures without live virus, enhancing safety and immunogenicity profiles. It targets prevention of poliomyelitis caused by poliovirus types 1, 2, and 3, aligning with WHO post-eradication strategies for safer vaccine alternatives. The vaccine is administered to infants and toddlers, with a Phase I/II trial initiated in Indonesia assessing safety and immunogenicity in specific age groups.[3][5][10]

Other names: 重组三价脊髓灰质炎疫苗(Sf-RVN细胞)VLP-IPV

Beyond the preview

Go deeper on CS-2036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-2036.